Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine
Idiopathic Multicentric Castleman Disease (iMCD) is a potentially life-threatening systemic disease whose complex symptomatology is due to cytokine dysregulation. We, herein, present a case of severe iMCD occurring in a previously healthy young man shortly after mRNA SARS-CoV-2 vaccination, respondi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/10/1725 |
| _version_ | 1797469727102074880 |
|---|---|
| author | Christian Hoffmann Thomas Wechselberger Heinz Drexel Susanne Dertinger Stefan Dirnhofer Sheila K. Pierson David C. Fajgenbaum Andreas Kessler |
| author_facet | Christian Hoffmann Thomas Wechselberger Heinz Drexel Susanne Dertinger Stefan Dirnhofer Sheila K. Pierson David C. Fajgenbaum Andreas Kessler |
| author_sort | Christian Hoffmann |
| collection | DOAJ |
| description | Idiopathic Multicentric Castleman Disease (iMCD) is a potentially life-threatening systemic disease whose complex symptomatology is due to cytokine dysregulation. We, herein, present a case of severe iMCD occurring in a previously healthy young man shortly after mRNA SARS-CoV-2 vaccination, responding to interleukin-6 blockade with siltuximab. Six months after the completion of siltuximab, the patient remained without any signs of iMCD or inflammation, indicating a temporal trigger of the disease. This case not only adds to the potential pathogenetic spectrum of MCD, but also extends the clinical picture of potential but rare adverse events following COVID-19 immunization. |
| first_indexed | 2024-03-09T19:24:17Z |
| format | Article |
| id | doaj.art-ca029a1c130b4e0e9b768b999d0c5421 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T19:24:17Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-ca029a1c130b4e0e9b768b999d0c54212023-11-24T03:04:58ZengMDPI AGVaccines2076-393X2022-10-011010172510.3390/vaccines10101725Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 VaccineChristian Hoffmann0Thomas Wechselberger1Heinz Drexel2Susanne Dertinger3Stefan Dirnhofer4Sheila K. Pierson5David C. Fajgenbaum6Andreas Kessler7ICH Study Center Hamburg, 20095 Hamburg, GermanyDepartment of Hematology, Oncology, Palliative Medicine, Hemostaseology, Provincial Hospital Bregenz, 6900 Bregenz, AustriaDepartment of Hematology, Oncology, Palliative Medicine, Hemostaseology, Provincial Hospital Bregenz, 6900 Bregenz, AustriaDepartment of Pathology, Academic Teaching Hospital Feldkirch, 6800 Feldkirch, AustriaDepartment of Pathology, University Hospital Basel, Schoenbeinstr. 40, CH-4031 Basel, SwitzerlandDepartment of Medicine, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19019, USADepartment of Medicine, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19019, USADepartment of Hematology, Oncology, Palliative Medicine, Hemostaseology, Provincial Hospital Bregenz, 6900 Bregenz, AustriaIdiopathic Multicentric Castleman Disease (iMCD) is a potentially life-threatening systemic disease whose complex symptomatology is due to cytokine dysregulation. We, herein, present a case of severe iMCD occurring in a previously healthy young man shortly after mRNA SARS-CoV-2 vaccination, responding to interleukin-6 blockade with siltuximab. Six months after the completion of siltuximab, the patient remained without any signs of iMCD or inflammation, indicating a temporal trigger of the disease. This case not only adds to the potential pathogenetic spectrum of MCD, but also extends the clinical picture of potential but rare adverse events following COVID-19 immunization.https://www.mdpi.com/2076-393X/10/10/1725Idiopathic Multicentric Castleman DiseasemRNA SARS-CoV-2 vaccineTAFRO syndromesiltuximab |
| spellingShingle | Christian Hoffmann Thomas Wechselberger Heinz Drexel Susanne Dertinger Stefan Dirnhofer Sheila K. Pierson David C. Fajgenbaum Andreas Kessler Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine Vaccines Idiopathic Multicentric Castleman Disease mRNA SARS-CoV-2 vaccine TAFRO syndrome siltuximab |
| title | Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine |
| title_full | Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine |
| title_fullStr | Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine |
| title_full_unstemmed | Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine |
| title_short | Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine |
| title_sort | idiopathic multicentric castleman disease occurring shortly after mrna sars cov 2 vaccine |
| topic | Idiopathic Multicentric Castleman Disease mRNA SARS-CoV-2 vaccine TAFRO syndrome siltuximab |
| url | https://www.mdpi.com/2076-393X/10/10/1725 |
| work_keys_str_mv | AT christianhoffmann idiopathicmulticentriccastlemandiseaseoccurringshortlyaftermrnasarscov2vaccine AT thomaswechselberger idiopathicmulticentriccastlemandiseaseoccurringshortlyaftermrnasarscov2vaccine AT heinzdrexel idiopathicmulticentriccastlemandiseaseoccurringshortlyaftermrnasarscov2vaccine AT susannedertinger idiopathicmulticentriccastlemandiseaseoccurringshortlyaftermrnasarscov2vaccine AT stefandirnhofer idiopathicmulticentriccastlemandiseaseoccurringshortlyaftermrnasarscov2vaccine AT sheilakpierson idiopathicmulticentriccastlemandiseaseoccurringshortlyaftermrnasarscov2vaccine AT davidcfajgenbaum idiopathicmulticentriccastlemandiseaseoccurringshortlyaftermrnasarscov2vaccine AT andreaskessler idiopathicmulticentriccastlemandiseaseoccurringshortlyaftermrnasarscov2vaccine |